Abacus Finance backs LongueVue's dental lab consolidation play with senior debt and equity co-invest
What's the deal? Abacus Finance GroupDealroom has a profile for this one. Try Dealroom → served as senior secured credit facilities administrative agent and lead arranger in a senior debt financing to support LongueVue CapitalDealroom has a profile for this one. Try Dealroom →'s investment in Apex Dental Laboratories Group. Abacus also made an equity co-investment in the dental lab network.
Apex Dental LaboratoryDealroom has a profile for this one. Try Dealroom → Group is a network of dental labs focused on customer service and consistent results. LongueVue Capital is a New Orleans-based equity investment firm founded in 2001, with over $800M in committed capital across five funds, focused on growth capital for middle-market companies.
Abacus, headquartered in New York, specialises in private credit for the lower middle market and has closed over $3.5B in financings since its founding in 2011. It targets debt financing opportunities of up to $60M for companies with EBITDA between $2M and $15M.
"We are always happy to support investments from LongueVue in one of their core industry verticals," said Tim Clifford, chief executive officer and founding partner of Abacus Finance. "Our success was a function of our speed, structural flexibility, and certainty of close."
Legal counsel was provided by Goulston & StorrsDealroom has a profile for this one. Try Dealroom →.
Why now? The deal reflects continued private equity interest in healthcare services — dental labs in particular — as ageing populations and advances in dental technology drive steady demand. LongueVue's repeated partnership with Abacus suggests an established relationship that speeds execution.
What could go wrong? Dental labs face margin pressure from consolidation, evolving insurance reimbursement models, and the rise of in-house digital dentistry tools that could reduce outsourced lab work. Leverage on a lower middle-market services business also carries inherent risk if demand softens.
The signal: Apex Dental Laboratory is tagged as a "breakout" stage company on Dealroom, suggesting meaningful momentum behind its consolidation model — and making it exactly the kind of platform play that attracts repeat sponsor-lender pairings. LongueVue's willingness to return to Abacus, and Abacus's decision to co-invest equity alongside its debt, signals high conviction on both sides that fragmented dental lab networks still offer a long consolidation runway in the lower middle market.
Read more: sfnet.com
